Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.

Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJ, Hsu TL, Yu AL, Wu CY, Wong CH.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2517-22. doi: 10.1073/pnas.1222649110. Epub 2013 Jan 25.


Immunogenicity study of Globo H analogues with modification at the reducing or nonreducing end of the tumor antigen.

Lee HY, Chen CY, Tsai TI, Li ST, Lin KH, Cheng YY, Ren CT, Cheng TJ, Wu CY, Wong CH.

J Am Chem Soc. 2014 Dec 3;136(48):16844-53. doi: 10.1021/ja508040d. Epub 2014 Nov 20.


Development of Globo-H cancer vaccine.

Danishefsky SJ, Shue YK, Chang MN, Wong CH.

Acc Chem Res. 2015 Mar 17;48(3):643-52. doi: 10.1021/ar5004187. Epub 2015 Feb 10.


Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.

Ragupathi G, Deshpande PP, Coltart DM, Kim HM, Williams LJ, Danishefsky SJ, Livingston PO.

Int J Cancer. 2002 May 10;99(2):207-12.


Synthesis and vaccine evaluation of the tumor-associated carbohydrate antigen RM2 from prostate cancer.

Chuang HY, Ren CT, Chao CA, Wu CY, Shivatare SS, Cheng TJ, Wu CY, Wong CH.

J Am Chem Soc. 2013 Jul 31;135(30):11140-50. doi: 10.1021/ja403609x. Epub 2013 Jul 17.


Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis.

Chang WW, Lee CH, Lee P, Lin J, Hsu CW, Hung JT, Lin JJ, Yu JC, Shao LE, Yu J, Wong CH, Yu AL.

Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11667-72. doi: 10.1073/pnas.0804979105. Epub 2008 Aug 6. Erratum in: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17206.


Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI.

J Clin Oncol. 2003 Dec 1;21(23):4292-8.


Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.


From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.

Zhu J, Wan Q, Lee D, Yang G, Spassova MK, Ouerfelli O, Ragupathi G, Damani P, Livingston PO, Danishefsky SJ.

J Am Chem Soc. 2009 Jul 8;131(26):9298-303. doi: 10.1021/ja901415s.


The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer.

Croce MV, Segal-Eiras A.

Drugs Today (Barc). 2002 Nov;38(11):759-68. Review.


Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudryashov V, Ragupathi G, Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2719-24.


Clinical development of the STn-KLH vaccine (Theratope).

Ibrahim NK, Murray JL.

Clin Breast Cancer. 2003 Feb;3 Suppl 4:S139-43. Review.


Synthesis and characterization of a novel chemically designed (Globo)3-DTPA-KLH antigen.

Hajmohammadi M, Siadat SD, Ghorbani M, Shafiee Ardestani M, Teimourian S, Asgari V, Ahangari Cohan R, Hajmohammadi M, Hajmohammadi A, Behzadi R, Rajab Nezhad S, Namvar Asl N.

Drug Des Devel Ther. 2014 Dec 22;9:217-39. doi: 10.2147/DDDT.S72530. eCollection 2015.


Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.

Hoffmann-Röder A, Kaiser A, Wagner S, Gaidzik N, Kowalczyk D, Westerlind U, Gerlitzki B, Schmitt E, Kunz H.

Angew Chem Int Ed Engl. 2010 Nov 2;49(45):8498-503. doi: 10.1002/anie.201003810. No abstract available.


Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.

Miles D, Papazisis K.

Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8. Review.


Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5710-5.


Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.

Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, Livingston PO.

Cancer Immunol Immunother. 2009 Sep;58(9):1397-405. doi: 10.1007/s00262-008-0654-7. Epub 2009 Feb 4.


Supplemental Content

Support Center